Invention Grant
- Patent Title: Substituted benzimidazole derivative as a modulator of TNF activity
-
Application No.: US16349734Application Date: 2017-12-08
-
Publication No.: US10669263B2Publication Date: 2020-06-02
- Inventor: Jag Paul Heer
- Applicant: UCB Biopharma SRL
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SRL
- Current Assignee: UCB Biopharma SRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@d467382
- International Application: PCT/EP2017/082092 WO 20171208
- International Announcement: WO2018/104534 WO 20180614
- Main IPC: A61K31/506
- IPC: A61K31/506 ; A61K31/4184 ; C07D403/04 ; A61P37/00 ; A61P25/28 ; A61P3/00 ; A61P9/00 ; A61P37/08 ; A61P29/00 ; A61P35/00

Abstract:
2-(5-{1-[2-(Difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20190284170A1 Substituted Benzimidazole Derivative as a Modulator of TNF Activity Public/Granted day:2019-09-19
Information query
IPC分类: